[{"to": "226", "prefix": "m of Action\n\n                     \n                        ", "from": "215", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " competitively inhibits HMG-CoA reductase, which is a rate-d"}, {"to": "1720", "prefix": "             \n                                 Absorption: ", "from": "1709", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " peak plasma concentrations are achieved about 1 hour after "}, {"to": "1975", "prefix": "rom 1 to 24 mg once daily. The absolute bioavailability of ", "from": "1964", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " oral solution is 51%. Administration of LIVALO with a high "}, {"to": "2084", "prefix": "of LIVALO with a high fat meal (50% fat content) decreases ", "from": "2073", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax  by 43% but does not significantly reduce pitavastatin"}, {"to": "2144", "prefix": "itavastatin Cmax  by 43% but does not significantly reduce ", "from": "2133", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUC. The Cmax and AUC of pitavastatin did not differ follow"}, {"to": "2182", "prefix": "significantly reduce pitavastatin AUC. The Cmax and AUC of ", "from": "2171", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " did not differ following evening or morning drug administra"}, {"to": "2297", "prefix": " drug administration. In healthy volunteers receiving 4 mg ", "from": "2286", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": ", the percent change from baseline for LDL-C following eveni"}, {"to": "2436", "prefix": "g was slightly greater than that following morning dosing. ", "from": "2425", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " was absorbed in the small intestine but very little in the "}, {"to": "2828", "prefix": "           \n                                 Distribution: ", "from": "2817", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " is more than 99% protein bound in human plasma, mainly to a"}, {"to": "3014", "prefix": "me of distribution is approximately 148 L.  Association of ", "from": "3003", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " and/or its metabolites with the blood cells is minimal.\n\n  "}, {"to": "3394", "prefix": "             \n                                 Metabolism: ", "from": "3383", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " is marginally metabolized by CYP2C9 and to a lesser extent "}, {"to": "3563", "prefix": "an plasma is the lactone which is formed via an ester-type ", "from": "3552", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " glucuronide conjugate by uridine 5'-diphosphate (UDP) glucu"}, {"to": "4066", "prefix": "activity of orally administered,  single 32 mg 14C-labeled ", "from": "4055", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " dose was excreted in urine, whereas a mean of 79%  of the d"}, {"to": "4576", "prefix": "                          Race: In pharmacokinetic studies ", "from": "4565", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax and AUC were 21 and 5% lower, respectively in Black or"}, {"to": "5262", "prefix": "c study which compared healthy male and female volunteers, ", "from": "5251", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax and AUC were 60 and 54% higher, respectively in female"}, {"to": "5824", "prefix": "compared healthy young and elderly (\u226565\u00a0years) volunteers, ", "from": "5813", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax and AUC were 10 and 30% higher, respectively, in the e"}, {"to": "6467", "prefix": "73 m2) and end stage renal disease receiving hemodialysis, ", "from": "6456", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUC0-inf is 102 and 86% higher than those of healthy volunt"}, {"to": "6565", "prefix": "gher than those of healthy volunteers, respectively, while ", "from": "6554", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax is 60 and 40% higher than those of healthy volunteers,"}, {"to": "6702", "prefix": "ctively. Patients received hemodialysis immediately before ", "from": "6691", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " dosing and did not undergo hemodialysis during the pharmaco"}, {"to": "6869", "prefix": " have 33 and 36% increases in the mean unbound fraction of ", "from": "6858", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " as compared to healthy volunteers and patients with moderat"}, {"to": "7424", "prefix": "healthy volunteers, the mean percentage of protein-unbound ", "from": "7413", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " was approximately 0.6%.\n\n                              The "}, {"to": "7531", "prefix": "                    The effect of mild renal impairment on ", "from": "7520", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " exposure has not been studied.\n\n                           "}, {"to": "7913", "prefix": "                    Hepatic Impairment: The disposition of ", "from": "7902", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " was compared in healthy volunteers and patients with variou"}, {"to": "8031", "prefix": "s with various degrees of hepatic impairment. The ratio of ", "from": "8020", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax between patients with moderate hepatic impairment (Chi"}, {"to": "8168", "prefix": "h B disease) and healthy volunteers was 2.7.  The ratio of ", "from": "8157", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUCinf between patients with moderate hepatic impairment an"}, {"to": "8284", "prefix": "c impairment and healthy volunteers was 3.8.  The ratio of ", "from": "8273", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax between patients with mild hepatic impairment (Child-P"}, {"to": "8417", "prefix": "h A disease) and healthy volunteers was 1.3.  The ratio of ", "from": "8406", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUCinf between patients with mild hepatic impairment and he"}, {"to": "8521", "prefix": "d hepatic impairment and healthy volunteers was 1.6.  Mean ", "from": "8510", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " t\u00bd for moderate hepatic impairment, mild hepatic impairment"}, {"to": "8993", "prefix": "            Drug-Drug Interactions: The principal route of ", "from": "8982", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " metabolism is glucuronidation via liver UGTs with subsequen"}, {"to": "9080", "prefix": "lucuronidation via liver UGTs with subsequent formation of ", "from": "9069", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " lactone. There is only minimal metabolism by the cytochrome"}, {"to": "9777", "prefix": "g warfarin should have their PT time or INR monitored when ", "from": "9766", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " is added to their therapy.\n\n                              \n"}, {"to": "226", "prefix": "m of Action\n\n                     \n                        ", "from": "215", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " competitively inhibits HMG-CoA reductase, which is a rate-d"}, {"to": "1720", "prefix": "             \n                                 Absorption: ", "from": "1709", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " peak plasma concentrations are achieved about 1 hour after "}, {"to": "1975", "prefix": "rom 1 to 24 mg once daily. The absolute bioavailability of ", "from": "1964", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " oral solution is 51%. Administration of LIVALO with a high "}, {"to": "2084", "prefix": "of LIVALO with a high fat meal (50% fat content) decreases ", "from": "2073", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax  by 43% but does not significantly reduce pitavastatin"}, {"to": "2144", "prefix": "itavastatin Cmax  by 43% but does not significantly reduce ", "from": "2133", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUC. The Cmax and AUC of pitavastatin did not differ follow"}, {"to": "2182", "prefix": "significantly reduce pitavastatin AUC. The Cmax and AUC of ", "from": "2171", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " did not differ following evening or morning drug administra"}, {"to": "2297", "prefix": " drug administration. In healthy volunteers receiving 4 mg ", "from": "2286", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": ", the percent change from baseline for LDL-C following eveni"}, {"to": "2436", "prefix": "g was slightly greater than that following morning dosing. ", "from": "2425", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " was absorbed in the small intestine but very little in the "}, {"to": "2828", "prefix": "           \n                                 Distribution: ", "from": "2817", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " is more than 99% protein bound in human plasma, mainly to a"}, {"to": "3014", "prefix": "me of distribution is approximately 148 L.  Association of ", "from": "3003", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " and/or its metabolites with the blood cells is minimal.\n\n  "}, {"to": "3394", "prefix": "             \n                                 Metabolism: ", "from": "3383", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " is marginally metabolized by CYP2C9 and to a lesser extent "}, {"to": "3563", "prefix": "an plasma is the lactone which is formed via an ester-type ", "from": "3552", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " glucuronide conjugate by uridine 5'-diphosphate (UDP) glucu"}, {"to": "4066", "prefix": "activity of orally administered,  single 32 mg 14C-labeled ", "from": "4055", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " dose was excreted in urine, whereas a mean of 79%  of the d"}, {"to": "4576", "prefix": "                          Race: In pharmacokinetic studies ", "from": "4565", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax and AUC were 21 and 5% lower, respectively in Black or"}, {"to": "5262", "prefix": "c study which compared healthy male and female volunteers, ", "from": "5251", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax and AUC were 60 and 54% higher, respectively in female"}, {"to": "5824", "prefix": "compared healthy young and elderly (\u226565\u00a0years) volunteers, ", "from": "5813", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax and AUC were 10 and 30% higher, respectively, in the e"}, {"to": "6467", "prefix": "73 m2) and end stage renal disease receiving hemodialysis, ", "from": "6456", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUC0-inf is 102 and 86% higher than those of healthy volunt"}, {"to": "6565", "prefix": "gher than those of healthy volunteers, respectively, while ", "from": "6554", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax is 60 and 40% higher than those of healthy volunteers,"}, {"to": "6702", "prefix": "ctively. Patients received hemodialysis immediately before ", "from": "6691", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " dosing and did not undergo hemodialysis during the pharmaco"}, {"to": "6869", "prefix": " have 33 and 36% increases in the mean unbound fraction of ", "from": "6858", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " as compared to healthy volunteers and patients with moderat"}, {"to": "7424", "prefix": "healthy volunteers, the mean percentage of protein-unbound ", "from": "7413", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " was approximately 0.6%.\n\n                              The "}, {"to": "7531", "prefix": "                    The effect of mild renal impairment on ", "from": "7520", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " exposure has not been studied.\n\n                           "}, {"to": "7913", "prefix": "                    Hepatic Impairment: The disposition of ", "from": "7902", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " was compared in healthy volunteers and patients with variou"}, {"to": "8031", "prefix": "s with various degrees of hepatic impairment. The ratio of ", "from": "8020", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax between patients with moderate hepatic impairment (Chi"}, {"to": "8168", "prefix": "h B disease) and healthy volunteers was 2.7.  The ratio of ", "from": "8157", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUCinf between patients with moderate hepatic impairment an"}, {"to": "8284", "prefix": "c impairment and healthy volunteers was 3.8.  The ratio of ", "from": "8273", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax between patients with mild hepatic impairment (Child-P"}, {"to": "8417", "prefix": "h A disease) and healthy volunteers was 1.3.  The ratio of ", "from": "8406", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUCinf between patients with mild hepatic impairment and he"}, {"to": "8521", "prefix": "d hepatic impairment and healthy volunteers was 1.6.  Mean ", "from": "8510", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " t\u00bd for moderate hepatic impairment, mild hepatic impairment"}, {"to": "8993", "prefix": "            Drug-Drug Interactions: The principal route of ", "from": "8982", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " metabolism is glucuronidation via liver UGTs with subsequen"}, {"to": "9080", "prefix": "lucuronidation via liver UGTs with subsequent formation of ", "from": "9069", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " lactone. There is only minimal metabolism by the cytochrome"}, {"to": "9777", "prefix": "g warfarin should have their PT time or INR monitored when ", "from": "9766", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861634", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " is added to their therapy.\n\n                              \n"}, {"to": "345", "prefix": "is a rate-determining enzyme involved with biosynthesis of ", "from": "335", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "cholesterol", "suffix": ", in a manner of competition with the substrate so that it i"}, {"to": "424", "prefix": "nner of competition with the substrate so that it inhibits ", "from": "414", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "cholesterol", "suffix": " synthesis in the liver. As a result, the expression of LDL-"}, {"to": "641", "prefix": " plasma TC decreases. Further, the sustained inhibition of ", "from": "631", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "cholesterol", "suffix": " synthesis in the liver decreases levels of very low density"}, {"to": "1021", "prefix": "        In a randomized, double-blind, placebo-controlled, ", "from": "1017", "name": "4-Way", "fullId": "http://purl.bioontology.org/ontology/RXNORM/672535", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "4-way", "suffix": " parallel, active-comparator study with moxifloxacin in 174 "}, {"to": "1073", "prefix": "o-controlled, 4-way parallel, active-comparator study with ", "from": "1062", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "moxifloxacin", "suffix": " in 174 healthy participants, LIVALO was not associated with"}, {"to": "1073", "prefix": "o-controlled, 4-way parallel, active-comparator study with ", "from": "1062", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/C104727", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "moxifloxacin", "suffix": " in 174 healthy participants, LIVALO was not associated with"}, {"to": "1109", "prefix": "rator study with moxifloxacin in 174 healthy participants, ", "from": "1104", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " was not associated with clinically meaningful prolongation "}, {"to": "1896", "prefix": "ed in an approximately dose-proportional manner for single ", "from": "1891", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " doses from 1 to 24 mg once daily. The absolute bioavailabil"}, {"to": "2022", "prefix": "ty of pitavastatin oral solution is 51%. Administration of ", "from": "2017", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " with a high fat meal (50% fat content) decreases pitavastat"}, {"to": "5379", "prefix": "n females. This had no effect on the efficacy or safety of ", "from": "5374", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " in women in clinical studies.\n\n                           \n"}, {"to": "5946", "prefix": "e elderly. This had no effect on the efficacy or safety of ", "from": "5941", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " in elderly subjects in clinical studies.\n\n                 "}, {"to": "7186", "prefix": " receiving hemodialysis were administered a single dose of ", "from": "7181", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " 4 mg.  The AUC0-inf and the Cmax were 36 and 18% higher, re"}, {"to": "9667", "prefix": "thy volunteers were unaffected by the co-administration of ", "from": "9662", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " 4\u00a0mg daily. However, patients receiving warfarin should hav"}, {"to": "9461", "prefix": "                         \n                                 ", "from": "9454", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Warfarin", "suffix": ": The steady-state pharmacodynamics (international normalize"}, {"to": "9594", "prefix": "o [INR] and prothrombin time [PT]) and pharmacokinetics of ", "from": "9587", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "warfarin", "suffix": " in healthy volunteers were unaffected by the co-administrat"}, {"to": "9716", "prefix": "stration of LIVALO 4\u00a0mg daily. However, patients receiving ", "from": "9709", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "warfarin", "suffix": " should have their PT time or INR monitored when pitavastati"}, {"to": "9461", "prefix": "                         \n                                 ", "from": "9454", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Warfarin", "suffix": ": The steady-state pharmacodynamics (international normalize"}, {"to": "9594", "prefix": "o [INR] and prothrombin time [PT]) and pharmacokinetics of ", "from": "9587", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "warfarin", "suffix": " in healthy volunteers were unaffected by the co-administrat"}, {"to": "9716", "prefix": "stration of LIVALO 4\u00a0mg daily. However, patients receiving ", "from": "9709", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "warfarin", "suffix": " should have their PT time or INR monitored when pitavastati"}, {"to": "9550", "prefix": "pharmacodynamics (international normalized ratio [INR] and ", "from": "9540", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "prothrombin", "suffix": " time [PT]) and pharmacokinetics of warfarin in healthy volu"}, {"to": "9550", "prefix": "pharmacodynamics (international normalized ratio [INR] and ", "from": "9540", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1441688", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "prothrombin", "suffix": " time [PT]) and pharmacokinetics of warfarin in healthy volu"}, {"to": "260", "prefix": "                        The precise mechanism of action of ", "from": "250", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " as a hypnotic is unknown, but its effect is believed to res"}, {"to": "477", "prefix": "to or allosterically coupled to benzodiazepine receptors.  ", "from": "467", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is a nonbenzodiazepine hypnotic that is a pyrrolopyrazine d"}, {"to": "1015", "prefix": "          \n                        The pharmacokinetics of ", "from": "1005", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " have been investigated in healthy subjects (adult and elder"}, {"to": "1310", "prefix": "r once-daily administration of 1, 3, and 6 mg for 7 days.  ", "from": "1300", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is rapidly absorbed, with a time to peak concentration (tma"}, {"to": "1960", "prefix": "                            \n                              ", "from": "1950", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is rapidly absorbed following oral administration.  Peak pl"}, {"to": "2120", "prefix": "ed within approximately 1 hour after oral administration.  ", "from": "2110", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is weakly bound to plasma protein (52-59%).  The large free"}, {"to": "2215", "prefix": "a protein (52-59%).  The large free fraction suggests that ", "from": "2205", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " disposition should not be affected by drug-drug interaction"}, {"to": "2346", "prefix": " caused by protein binding.  The blood-to-plasma ratio for ", "from": "2336", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is less than one, indicating no selective uptake by red blo"}, {"to": "2829", "prefix": "                            Following oral administration, ", "from": "2819", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is extensively metabolized by oxidation and demethylation. "}, {"to": "3071", "prefix": "ds to GABA receptors with substantially lower potency than ", "from": "3061", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ", and the former compound shows no significant binding to th"}, {"to": "3249", "prefix": "YP3A4 and CYP2E1 enzymes are involved in the metabolism of ", "from": "3239", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ".  Eszopiclone did not show any inhibitory potential on CYP4"}, {"to": "3263", "prefix": "E1 enzymes are involved in the metabolism of eszopiclone.  ", "from": "3253", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " did not show any inhibitory potential on CYP450 1A2, 2A6, 2"}, {"to": "3797", "prefix": " \n                              After oral administration, ", "from": "3787", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is eliminated with a mean t1/2 of approximately 6 hours.  U"}, {"to": "4017", "prefix": "olites.  A similar excretion profile would be expected for ", "from": "4007", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ", the S-isomer of racemic zopiclone.  Less than 10% of the o"}, {"to": "4107", "prefix": "cemic zopiclone.  Less than 10% of the orally administered ", "from": "4097", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " dose is excreted in the urine as parent drug.\n\n            "}, {"to": "4592", "prefix": "       In healthy adults, administration of a 3 mg dose of ", "from": "4582", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " after a high-fat meal resulted in no change in AUC, a reduc"}, {"to": "5777", "prefix": "tal exposure (AUC) and a slightly prolonged elimination of ", "from": "5767", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " (t1/2 approximately 9\u00a0hours).  Cmax was unchanged.  Therefo"}, {"to": "6374", "prefix": "                                   The pharmacokinetics of ", "from": "6364", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " in men and women are similar.\n\n                            "}, {"to": "6934", "prefix": "f data on all subjects participating in Phase 1 studies of ", "from": "6924", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ", the pharmacokinetics for all races studied appeared simila"}, {"to": "7492", "prefix": "                                Pharmacokinetics of a 2 mg ", "from": "7482", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " dose were assessed in 16 healthy volunteers and in 8\u00a0subjec"}, {"to": "8495", "prefix": "                                   The pharmacokinetics of ", "from": "8485", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " were studied in 24 patients with mild, moderate, or severe "}, {"to": "8806", "prefix": "impairment, since less than 10% of the orally administered ", "from": "8796", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " dose is excreted in the urine as parent drug.\n\n            "}, {"to": "9313", "prefix": "                            \n                              ", "from": "9303", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is metabolized by CYP3A4 and CYP2E1 via demethylation and o"}, {"to": "9465", "prefix": "no pharmacokinetic or pharmacodynamic interactions between ", "from": "9455", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and paroxetine. When eszopiclone was coadministered with ol"}, {"to": "9498", "prefix": "amic interactions between eszopiclone and paroxetine. When ", "from": "9488", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " was coadministered with olanzapine, no pharmacokinetic inte"}, {"to": "9603", "prefix": ", no pharmacokinetic interaction was detected in levels of ", "from": "9593", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " or olanzapine, but a pharmacodynamic interaction was seen o"}, {"to": "9712", "prefix": "nteraction was seen on a measure of psychomotor function.  ", "from": "9702", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " and lorazepam decreased each other's Cmax by 22%.  Coadmini"}, {"to": "9795", "prefix": "m decreased each other's Cmax by 22%.  Coadministration of ", "from": "9785", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " 3 mg to subjects receiving ketoconazole, a potent inhibitor"}, {"to": "9950", "prefix": "for 5 days, resulted in a 2.2-fold increase in exposure to ", "from": "9940", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ".  Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respe"}, {"to": "10610", "prefix": "           Paroxetine:  Coadministration of single dose of ", "from": "10600", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and paroxetine produced no pharmacokinetic or pharmacodynam"}, {"to": "11278", "prefix": "           Lorazepam:  Coadministration of single doses of ", "from": "11268", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and lorazepam did not have clinically relevant effects on t"}, {"to": "12404", "prefix": "                                Digoxin:  A single dose of ", "from": "12394", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " 3 mg did not affect the pharmacokinetics of digoxin measure"}, {"to": "12671", "prefix": "        \n                                       Warfarin:  ", "from": "12661", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " 3 mg administered daily for 5 days did not affect the pharm"}, {"to": "13379", "prefix": "                      \n                                    ", "from": "13369", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is not highly bound to plasma proteins (52-59% bound); ther"}, {"to": "13476", "prefix": "sma proteins (52-59% bound); therefore, the disposition of ", "from": "13466", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is not expected to be sensitive to alterations in protein b"}, {"to": "13574", "prefix": "tive to alterations in protein binding.  Administration of ", "from": "13564", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " 3 mg to a patient taking another drug that is highly protei"}, {"to": "260", "prefix": "                        The precise mechanism of action of ", "from": "250", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " as a hypnotic is unknown, but its effect is believed to res"}, {"to": "477", "prefix": "to or allosterically coupled to benzodiazepine receptors.  ", "from": "467", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is a nonbenzodiazepine hypnotic that is a pyrrolopyrazine d"}, {"to": "1015", "prefix": "          \n                        The pharmacokinetics of ", "from": "1005", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " have been investigated in healthy subjects (adult and elder"}, {"to": "1310", "prefix": "r once-daily administration of 1, 3, and 6 mg for 7 days.  ", "from": "1300", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is rapidly absorbed, with a time to peak concentration (tma"}, {"to": "1500", "prefix": "-life (t1/2) of approximately 6 hours.  In healthy adults, ", "from": "1494", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " does not accumulate with once-daily administration, and its"}, {"to": "1960", "prefix": "                            \n                              ", "from": "1950", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is rapidly absorbed following oral administration.  Peak pl"}, {"to": "2120", "prefix": "ed within approximately 1 hour after oral administration.  ", "from": "2110", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is weakly bound to plasma protein (52-59%).  The large free"}, {"to": "2215", "prefix": "a protein (52-59%).  The large free fraction suggests that ", "from": "2205", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " disposition should not be affected by drug-drug interaction"}, {"to": "2346", "prefix": " caused by protein binding.  The blood-to-plasma ratio for ", "from": "2336", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is less than one, indicating no selective uptake by red blo"}, {"to": "2829", "prefix": "                            Following oral administration, ", "from": "2819", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is extensively metabolized by oxidation and demethylation. "}, {"to": "3071", "prefix": "ds to GABA receptors with substantially lower potency than ", "from": "3061", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ", and the former compound shows no significant binding to th"}, {"to": "3249", "prefix": "YP3A4 and CYP2E1 enzymes are involved in the metabolism of ", "from": "3239", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ".  Eszopiclone did not show any inhibitory potential on CYP4"}, {"to": "3263", "prefix": "E1 enzymes are involved in the metabolism of eszopiclone.  ", "from": "3253", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " did not show any inhibitory potential on CYP450 1A2, 2A6, 2"}, {"to": "3797", "prefix": " \n                              After oral administration, ", "from": "3787", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is eliminated with a mean t1/2 of approximately 6 hours.  U"}, {"to": "4017", "prefix": "olites.  A similar excretion profile would be expected for ", "from": "4007", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ", the S-isomer of racemic zopiclone.  Less than 10% of the o"}, {"to": "4107", "prefix": "cemic zopiclone.  Less than 10% of the orally administered ", "from": "4097", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " dose is excreted in the urine as parent drug.\n\n            "}, {"to": "4592", "prefix": "       In healthy adults, administration of a 3 mg dose of ", "from": "4582", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " after a high-fat meal resulted in no change in AUC, a reduc"}, {"to": "4801", "prefix": "remained unchanged, approximately 6 hours.  The effects of ", "from": "4795", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " on sleep onset may be reduced if it is taken with or immedi"}, {"to": "5777", "prefix": "tal exposure (AUC) and a slightly prolonged elimination of ", "from": "5767", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " (t1/2 approximately 9\u00a0hours).  Cmax was unchanged.  Therefo"}, {"to": "6374", "prefix": "                                   The pharmacokinetics of ", "from": "6364", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " in men and women are similar.\n\n                            "}, {"to": "6934", "prefix": "f data on all subjects participating in Phase 1 studies of ", "from": "6924", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ", the pharmacokinetics for all races studied appeared simila"}, {"to": "7492", "prefix": "                                Pharmacokinetics of a 2 mg ", "from": "7482", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " dose were assessed in 16 healthy volunteers and in 8\u00a0subjec"}, {"to": "7901", "prefix": "s recommended for patients with severe hepatic impairment. ", "from": "7895", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " should be used with caution in patients with hepatic impair"}, {"to": "8495", "prefix": "                                   The pharmacokinetics of ", "from": "8485", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " were studied in 24 patients with mild, moderate, or severe "}, {"to": "8806", "prefix": "impairment, since less than 10% of the orally administered ", "from": "8796", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " dose is excreted in the urine as parent drug.\n\n            "}, {"to": "9313", "prefix": "                            \n                              ", "from": "9303", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is metabolized by CYP3A4 and CYP2E1 via demethylation and o"}, {"to": "9465", "prefix": "no pharmacokinetic or pharmacodynamic interactions between ", "from": "9455", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and paroxetine. When eszopiclone was coadministered with ol"}, {"to": "9498", "prefix": "amic interactions between eszopiclone and paroxetine. When ", "from": "9488", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " was coadministered with olanzapine, no pharmacokinetic inte"}, {"to": "9603", "prefix": ", no pharmacokinetic interaction was detected in levels of ", "from": "9593", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " or olanzapine, but a pharmacodynamic interaction was seen o"}, {"to": "9712", "prefix": "nteraction was seen on a measure of psychomotor function.  ", "from": "9702", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " and lorazepam decreased each other's Cmax by 22%.  Coadmini"}, {"to": "9795", "prefix": "m decreased each other's Cmax by 22%.  Coadministration of ", "from": "9785", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " 3 mg to subjects receiving ketoconazole, a potent inhibitor"}, {"to": "9950", "prefix": "for 5 days, resulted in a 2.2-fold increase in exposure to ", "from": "9940", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ".  Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respe"}, {"to": "10026", "prefix": "d t1/2 were increased 1.4-fold and 1.3-fold, respectively. ", "from": "10020", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " would not be expected to alter the clearance of drugs metab"}, {"to": "10610", "prefix": "           Paroxetine:  Coadministration of single dose of ", "from": "10600", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and paroxetine produced no pharmacokinetic or pharmacodynam"}, {"to": "11278", "prefix": "           Lorazepam:  Coadministration of single doses of ", "from": "11268", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and lorazepam did not have clinically relevant effects on t"}, {"to": "12404", "prefix": "                                Digoxin:  A single dose of ", "from": "12394", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " 3 mg did not affect the pharmacokinetics of digoxin measure"}, {"to": "12671", "prefix": "        \n                                       Warfarin:  ", "from": "12661", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " 3 mg administered daily for 5 days did not affect the pharm"}, {"to": "13379", "prefix": "                      \n                                    ", "from": "13369", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is not highly bound to plasma proteins (52-59% bound); ther"}, {"to": "13476", "prefix": "sma proteins (52-59% bound); therefore, the disposition of ", "from": "13466", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is not expected to be sensitive to alterations in protein b"}, {"to": "13574", "prefix": "tive to alterations in protein binding.  Administration of ", "from": "13564", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " 3 mg to a patient taking another drug that is highly protei"}, {"to": "354", "prefix": "its effect is believed to result from its interaction with ", "from": "351", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "GABA", "suffix": "-receptor complexes at binding domains located close to or a"}, {"to": "3011", "prefix": "nd (S)-N-desmethyl zopiclone; the latter compound binds to ", "from": "3008", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "GABA", "suffix": " receptors with substantially lower potency than eszopiclone"}, {"to": "453", "prefix": "ding domains located close to or allosterically coupled to ", "from": "440", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "benzodiazepine", "suffix": " receptors.  Eszopiclone is a nonbenzodiazepine hypnotic tha"}, {"to": "668", "prefix": "ucture unrelated to pyrazolopyrimidines, imidazopyridines, ", "from": "654", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "benzodiazepines", "suffix": ", barbiturates, or other drugs with known hypnotic propertie"}, {"to": "1500", "prefix": "-life (t1/2) of approximately 6 hours.  In healthy adults, ", "from": "1494", "name": "Lunesta", "fullId": "http://purl.bioontology.org/ontology/RXNORM/540404", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " does not accumulate with once-daily administration, and its"}, {"to": "4801", "prefix": "remained unchanged, approximately 6 hours.  The effects of ", "from": "4795", "name": "Lunesta", "fullId": "http://purl.bioontology.org/ontology/RXNORM/540404", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " on sleep onset may be reduced if it is taken with or immedi"}, {"to": "7901", "prefix": "s recommended for patients with severe hepatic impairment. ", "from": "7895", "name": "Lunesta", "fullId": "http://purl.bioontology.org/ontology/RXNORM/540404", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " should be used with caution in patients with hepatic impair"}, {"to": "10026", "prefix": "d t1/2 were increased 1.4-fold and 1.3-fold, respectively. ", "from": "10020", "name": "Lunesta", "fullId": "http://purl.bioontology.org/ontology/RXNORM/540404", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " would not be expected to alter the clearance of drugs metab"}, {"to": "2938", "prefix": "and demethylation.  The primary plasma metabolites are (S)-", "from": "2930", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40001", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": "-N-oxide and (S)-N-desmethyl zopiclone; the latter compound "}, {"to": "2976", "prefix": " metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl ", "from": "2968", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40001", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": "; the latter compound binds to GABA receptors with substanti"}, {"to": "3902", "prefix": "proximately 6 hours.  Up to 75% of an oral dose of racemic ", "from": "3894", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40001", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": " is excreted in the urine, primarily as metabolites.  A simi"}, {"to": "4052", "prefix": "would be expected for eszopiclone, the S-isomer of racemic ", "from": "4044", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40001", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": ".  Less than 10% of the orally administered eszopiclone dose"}, {"to": "2938", "prefix": "and demethylation.  The primary plasma metabolites are (S)-", "from": "2930", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515050", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": "-N-oxide and (S)-N-desmethyl zopiclone; the latter compound "}, {"to": "2976", "prefix": " metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl ", "from": "2968", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515050", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": "; the latter compound binds to GABA receptors with substanti"}, {"to": "3902", "prefix": "proximately 6 hours.  Up to 75% of an oral dose of racemic ", "from": "3894", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515050", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": " is excreted in the urine, primarily as metabolites.  A simi"}, {"to": "4052", "prefix": "would be expected for eszopiclone, the S-isomer of racemic ", "from": "4044", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515050", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": ".  Less than 10% of the orally administered eszopiclone dose"}, {"to": "9480", "prefix": "ic or pharmacodynamic interactions between eszopiclone and ", "from": "9471", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "paroxetine", "suffix": ". When eszopiclone was coadministered with olanzapine, no ph"}, {"to": "10561", "prefix": "                   \n                                       ", "from": "10552", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Paroxetine", "suffix": ":  Coadministration of single dose of eszopiclone and paroxe"}, {"to": "10625", "prefix": "etine:  Coadministration of single dose of eszopiclone and ", "from": "10616", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "paroxetine", "suffix": " produced no pharmacokinetic or pharmacodynamic interaction."}, {"to": "9480", "prefix": "ic or pharmacodynamic interactions between eszopiclone and ", "from": "9471", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "paroxetine", "suffix": ". When eszopiclone was coadministered with olanzapine, no ph"}, {"to": "10561", "prefix": "                   \n                                       ", "from": "10552", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Paroxetine", "suffix": ":  Coadministration of single dose of eszopiclone and paroxe"}, {"to": "10625", "prefix": "etine:  Coadministration of single dose of eszopiclone and ", "from": "10616", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "paroxetine", "suffix": " produced no pharmacokinetic or pharmacodynamic interaction."}, {"to": "9533", "prefix": "e and paroxetine. When eszopiclone was coadministered with ", "from": "9524", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "olanzapine", "suffix": ", no pharmacokinetic interaction was detected in levels of e"}, {"to": "9617", "prefix": "netic interaction was detected in levels of eszopiclone or ", "from": "9608", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "olanzapine", "suffix": ", but a pharmacodynamic interaction was seen on a measure of"}, {"to": "9533", "prefix": "e and paroxetine. When eszopiclone was coadministered with ", "from": "9524", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/61381", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "olanzapine", "suffix": ", no pharmacokinetic interaction was detected in levels of e"}, {"to": "9617", "prefix": "netic interaction was detected in levels of eszopiclone or ", "from": "9608", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/61381", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "olanzapine", "suffix": ", but a pharmacodynamic interaction was seen on a measure of"}, {"to": "9726", "prefix": "een on a measure of psychomotor function.  Eszopiclone and ", "from": "9718", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "lorazepam", "suffix": " decreased each other's Cmax by 22%.  Coadministration of es"}, {"to": "11228", "prefix": "                   \n                                       ", "from": "11220", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Lorazepam", "suffix": ":  Coadministration of single doses of eszopiclone and loraz"}, {"to": "11292", "prefix": "epam:  Coadministration of single doses of eszopiclone and ", "from": "11284", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "lorazepam", "suffix": " did not have clinically relevant effects on the pharmacodyn"}, {"to": "9726", "prefix": "een on a measure of psychomotor function.  Eszopiclone and ", "from": "9718", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D008140", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "lorazepam", "suffix": " decreased each other's Cmax by 22%.  Coadministration of es"}, {"to": "11228", "prefix": "                   \n                                       ", "from": "11220", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D008140", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Lorazepam", "suffix": ":  Coadministration of single doses of eszopiclone and loraz"}, {"to": "11292", "prefix": "epam:  Coadministration of single doses of eszopiclone and ", "from": "11284", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D008140", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "lorazepam", "suffix": " did not have clinically relevant effects on the pharmacodyn"}, {"to": "9835", "prefix": "Coadministration of eszopiclone 3 mg to subjects receiving ", "from": "9824", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "ketoconazole", "suffix": ", a potent inhibitor of CYP3A4, 400\u00a0mg daily for 5 days, res"}, {"to": "9835", "prefix": "Coadministration of eszopiclone 3 mg to subjects receiving ", "from": "9824", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "ketoconazole", "suffix": ", a potent inhibitor of CYP3A4, 400\u00a0mg daily for 5 days, res"}, {"to": "12373", "prefix": "                   \n                                       ", "from": "12367", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Digoxin", "suffix": ":  A single dose of eszopiclone 3 mg did not affect the phar"}, {"to": "12456", "prefix": "of eszopiclone 3 mg did not affect the pharmacokinetics of ", "from": "12450", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "digoxin", "suffix": " measured at steady state following dosing of 0.5 mg twice d"}, {"to": "12373", "prefix": "                   \n                                       ", "from": "12367", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Digoxin", "suffix": ":  A single dose of eszopiclone 3 mg did not affect the phar"}, {"to": "12456", "prefix": "of eszopiclone 3 mg did not affect the pharmacokinetics of ", "from": "12450", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "digoxin", "suffix": " measured at steady state following dosing of 0.5 mg twice d"}, {"to": "12657", "prefix": "                   \n                                       ", "from": "12650", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Warfarin", "suffix": ":  Eszopiclone 3 mg administered daily for 5 days did not af"}, {"to": "12766", "prefix": " 5 days did not affect the pharmacokinetics of (R)- or (S)-", "from": "12759", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "warfarin", "suffix": ", nor were there any changes in the pharmacodynamic profile "}, {"to": "12891", "prefix": "e (prothrombin time) following a single 25 mg oral dose of ", "from": "12884", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "warfarin", "suffix": ".\n\n                                 \n                       "}, {"to": "12657", "prefix": "                   \n                                       ", "from": "12650", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Warfarin", "suffix": ":  Eszopiclone 3 mg administered daily for 5 days did not af"}, {"to": "12766", "prefix": " 5 days did not affect the pharmacokinetics of (R)- or (S)-", "from": "12759", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "warfarin", "suffix": ", nor were there any changes in the pharmacodynamic profile "}, {"to": "12891", "prefix": "e (prothrombin time) following a single 25 mg oral dose of ", "from": "12884", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "warfarin", "suffix": ".\n\n                                 \n                       "}, {"to": "12838", "prefix": "nor were there any changes in the pharmacodynamic profile (", "from": "12828", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "prothrombin", "suffix": " time) following a single 25 mg oral dose of warfarin.\n\n    "}, {"to": "12838", "prefix": "nor were there any changes in the pharmacodynamic profile (", "from": "12828", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1441688", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "prothrombin", "suffix": " time) following a single 25 mg oral dose of warfarin.\n\n    "}, {"to": "371", "prefix": "other psychiatric disorders. Anyone considering the use of ", "from": "365", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": " or any other antidepressant in a child, adolescent or young"}, {"to": "1147", "prefix": "r close observation and communication with the prescriber. ", "from": "1141", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": " is not approved for use in pediatric patients. (See Warning"}, {"to": "128", "prefix": "        Hepatic microsomal enzyme inducing agents, such as ", "from": "116", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "carbamazepine", "suffix": ", were found to significantly increase the clearance of thio"}, {"to": "128", "prefix": "        Hepatic microsomal enzyme inducing agents, such as ", "from": "116", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002220", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "carbamazepine", "suffix": ", were found to significantly increase the clearance of thio"}, {"to": "195", "prefix": "ine, were found to significantly increase the clearance of ", "from": "185", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013888", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "thiothixene", "suffix": ". Patients receiving these drugs should be observed for sign"}, {"to": "279", "prefix": "eiving these drugs should be observed for signs of reduced ", "from": "269", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013888", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "thiothixene", "suffix": " effectiveness4,5.\n                        Due to a possible"}, {"to": "490", "prefix": "e observed closely for signs of excessive hypotension when ", "from": "480", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013888", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "thiothixene", "suffix": " is added to their drug regimen6.\n                     \n    "}, {"to": "195", "prefix": "ine, were found to significantly increase the clearance of ", "from": "185", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10510", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "thiothixene", "suffix": ". Patients receiving these drugs should be observed for sign"}, {"to": "279", "prefix": "eiving these drugs should be observed for signs of reduced ", "from": "269", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10510", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "thiothixene", "suffix": " effectiveness4,5.\n                        Due to a possible"}, {"to": "490", "prefix": "e observed closely for signs of excessive hypotension when ", "from": "480", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10510", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "thiothixene", "suffix": " is added to their drug regimen6.\n                     \n    "}, {"to": "198", "prefix": "nhibitors in combination with serotoninergic agents (e.g., ", "from": "184", "name": "Dexfenfluramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D020372", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "dexfenfluramine", "suffix": ", fluoxetine, fluvoxamine, paroxetine, sertraline, citalopra"}, {"to": "198", "prefix": "nhibitors in combination with serotoninergic agents (e.g., ", "from": "184", "name": "Dexfenfluramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3268", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "dexfenfluramine", "suffix": ", fluoxetine, fluvoxamine, paroxetine, sertraline, citalopra"}, {"to": "210", "prefix": "ination with serotoninergic agents (e.g., dexfenfluramine, ", "from": "201", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "fluoxetine", "suffix": ", fluvoxamine, paroxetine, sertraline, citalopram, venlafaxi"}, {"to": "210", "prefix": "ination with serotoninergic agents (e.g., dexfenfluramine, ", "from": "201", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "fluoxetine", "suffix": ", fluvoxamine, paroxetine, sertraline, citalopram, venlafaxi"}, {"to": "223", "prefix": " serotoninergic agents (e.g., dexfenfluramine, fluoxetine, ", "from": "213", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42355", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "fluvoxamine", "suffix": ", paroxetine, sertraline, citalopram, venlafaxine) there hav"}, {"to": "223", "prefix": " serotoninergic agents (e.g., dexfenfluramine, fluoxetine, ", "from": "213", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "fluvoxamine", "suffix": ", paroxetine, sertraline, citalopram, venlafaxine) there hav"}, {"to": "235", "prefix": "ic agents (e.g., dexfenfluramine, fluoxetine, fluvoxamine, ", "from": "226", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "paroxetine", "suffix": ", sertraline, citalopram, venlafaxine) there have been repor"}, {"to": "235", "prefix": "ic agents (e.g., dexfenfluramine, fluoxetine, fluvoxamine, ", "from": "226", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "paroxetine", "suffix": ", sertraline, citalopram, venlafaxine) there have been repor"}, {"to": "247", "prefix": ".g., dexfenfluramine, fluoxetine, fluvoxamine, paroxetine, ", "from": "238", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "sertraline", "suffix": ", citalopram, venlafaxine) there have been reports of seriou"}, {"to": "247", "prefix": ".g., dexfenfluramine, fluoxetine, fluvoxamine, paroxetine, ", "from": "238", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "sertraline", "suffix": ", citalopram, venlafaxine) there have been reports of seriou"}, {"to": "259", "prefix": "luramine, fluoxetine, fluvoxamine, paroxetine, sertraline, ", "from": "250", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "citalopram", "suffix": ", venlafaxine) there have been reports of serious, sometimes"}, {"to": "259", "prefix": "luramine, fluoxetine, fluvoxamine, paroxetine, sertraline, ", "from": "250", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2556", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "citalopram", "suffix": ", venlafaxine) there have been reports of serious, sometimes"}, {"to": "272", "prefix": "uoxetine, fluvoxamine, paroxetine, sertraline, citalopram, ", "from": "262", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "venlafaxine", "suffix": ") there have been reports of serious, sometimes fatal, react"}, {"to": "272", "prefix": "uoxetine, fluvoxamine, paroxetine, sertraline, citalopram, ", "from": "262", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "venlafaxine", "suffix": ") there have been reports of serious, sometimes fatal, react"}, {"to": "352", "prefix": "en reports of serious, sometimes fatal, reactions. Because ", "from": "347", "name": "Nardil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203799", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "NARDIL", "suffix": " is a monoamine oxidase (MAO) inhibitor, NARDIL should not b"}, {"to": "399", "prefix": "ns. Because NARDIL is a monoamine oxidase (MAO) inhibitor, ", "from": "394", "name": "Nardil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203799", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "NARDIL", "suffix": " should not be used concomitantly with a serotoninergic agen"}, {"to": "352", "prefix": "en reports of serious, sometimes fatal, reactions. Because ", "from": "347", "name": "Phenelzine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010624", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "NARDIL", "suffix": " is a monoamine oxidase (MAO) inhibitor, NARDIL should not b"}, {"to": "399", "prefix": "ns. Because NARDIL is a monoamine oxidase (MAO) inhibitor, ", "from": "394", "name": "Phenelzine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010624", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "NARDIL", "suffix": " should not be used concomitantly with a serotoninergic agen"}, {"to": "540", "prefix": "TRAINDICATIONS).\n                        Administration of ", "from": "529", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5036", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "guanethidine", "suffix": " to patients receiving an MAO inhibitor can produce moderate"}, {"to": "765", "prefix": "ween withdrawal of the MAO inhibitor and the initiation of ", "from": "754", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5036", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "guanethidine", "suffix": ". (see CONTRAINDICATIONS)\n                     \n            "}, {"to": "540", "prefix": "TRAINDICATIONS).\n                        Administration of ", "from": "529", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006145", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "guanethidine", "suffix": " to patients receiving an MAO inhibitor can produce moderate"}, {"to": "765", "prefix": "ween withdrawal of the MAO inhibitor and the initiation of ", "from": "754", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006145", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "guanethidine", "suffix": ". (see CONTRAINDICATIONS)\n                     \n            "}, {"to": "89", "prefix": "               \n               \n                  Although ", "from": "83", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " HCl does have H1 and H2 histamine receptor blocking actions"}, {"to": "187", "prefix": "ne receptor blocking actions, the exact mechanism by which ", "from": "181", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " exerts its antipruritic effect is unknown. PRUDOXIN Cream c"}, {"to": "239", "prefix": "y which doxepin exerts its antipruritic effect is unknown. ", "from": "232", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream can produce drowsiness which may reduce awareness, in"}, {"to": "391", "prefix": "itic symptoms. In 19 pruritic eczema patients treated with ", "from": "384", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream, plasma doxepin concentrations ranged from nondetecta"}, {"to": "413", "prefix": "uritic eczema patients treated with PRUDOXIN Cream, plasma ", "from": "407", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " concentrations ranged from nondetectable to 47 ng/mL from p"}, {"to": "547", "prefix": "eous absorption. Plasma levels from topical application of ", "from": "540", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream can result in CNS and other systemic side effects.\n  "}, {"to": "675", "prefix": "              Once absorbed into the systemic circulation, ", "from": "669", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " undergoes hepatic metabolism that results in conversion to "}, {"to": "1005", "prefix": " is not affected by multiple dosing. Plasma levels of both ", "from": "999", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " and desmethyldoxepin are highly variable and are poorly cor"}, {"to": "1287", "prefix": "ations affect the metabolism and subsequent elimination of ", "from": "1281", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": ". (See PRECAUTIONS - Drug Interactions.)\n               \n   "}, {"to": "89", "prefix": "               \n               \n                  Although ", "from": "83", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3638", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " HCl does have H1 and H2 histamine receptor blocking actions"}, {"to": "187", "prefix": "ne receptor blocking actions, the exact mechanism by which ", "from": "181", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3638", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " exerts its antipruritic effect is unknown. PRUDOXIN Cream c"}, {"to": "413", "prefix": "uritic eczema patients treated with PRUDOXIN Cream, plasma ", "from": "407", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3638", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " concentrations ranged from nondetectable to 47 ng/mL from p"}, {"to": "675", "prefix": "              Once absorbed into the systemic circulation, ", "from": "669", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3638", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " undergoes hepatic metabolism that results in conversion to "}, {"to": "1005", "prefix": " is not affected by multiple dosing. Plasma levels of both ", "from": "999", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3638", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " and desmethyldoxepin are highly variable and are poorly cor"}, {"to": "1287", "prefix": "ations affect the metabolism and subsequent elimination of ", "from": "1281", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3638", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": ". (See PRECAUTIONS - Drug Interactions.)\n               \n   "}, {"to": "123", "prefix": "                  Although doxepin HCl does have H1 and H2 ", "from": "115", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "histamine", "suffix": " receptor blocking actions, the exact mechanism by which dox"}, {"to": "123", "prefix": "                  Although doxepin HCl does have H1 and H2 ", "from": "115", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "histamine", "suffix": " receptor blocking actions, the exact mechanism by which dox"}, {"to": "239", "prefix": "y which doxepin exerts its antipruritic effect is unknown. ", "from": "232", "name": "Prudoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/261625", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream can produce drowsiness which may reduce awareness, in"}, {"to": "391", "prefix": "itic symptoms. In 19 pruritic eczema patients treated with ", "from": "384", "name": "Prudoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/261625", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream, plasma doxepin concentrations ranged from nondetecta"}, {"to": "547", "prefix": "eous absorption. Plasma levels from topical application of ", "from": "540", "name": "Prudoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/261625", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream can result in CNS and other systemic side effects.\n  "}, {"to": "776", "prefix": "ism that results in conversion to pharmacologically-active ", "from": "761", "name": "desmethyldoxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/C028701", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "desmethyldoxepin", "suffix": ". Further glucuronidation results in urinary excretion of th"}, {"to": "887", "prefix": " urinary excretion of the parent drug and its metabolites. ", "from": "872", "name": "desmethyldoxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/C028701", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "Desmethyldoxepin", "suffix": " has a half-life that ranges from 28 to 52 hours and is not "}, {"to": "1026", "prefix": "cted by multiple dosing. Plasma levels of both doxepin and ", "from": "1011", "name": "desmethyldoxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/C028701", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "desmethyldoxepin", "suffix": " are highly variable and are poorly correlated with dosage. "}, {"to": "323", "prefix": "n reports of adverse reactions upon the discontinuation of ", "from": "317", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " (mirtazapine) Tablets (particularly when abrupt), including"}, {"to": "336", "prefix": " of adverse reactions upon the discontinuation of REMERON (", "from": "326", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ") Tablets (particularly when abrupt), including but not limi"}, {"to": "934", "prefix": "e.\n                              Patients currently taking ", "from": "928", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " should NOT discontinue treatment abruptly, due to risk of d"}, {"to": "1100", "prefix": "t a medical decision is made to discontinue treatment with ", "from": "1094", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ", a gradual reduction in the dose, rather than an abrupt ces"}, {"to": "2262", "prefix": "Hyponatremia has been reported very rarely with the use of ", "from": "2252", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ". Caution should be exercised in patients at risk, such as e"}, {"to": "2809", "prefix": "s, somnolence was reported in 54% of patients treated with ", "from": "2803", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " (mirtazapine) Tablets, compared to 18% for placebo and 60% "}, {"to": "2822", "prefix": "ence was reported in 54% of patients treated with REMERON (", "from": "2812", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ") Tablets, compared to 18% for placebo and 60% for amitripty"}, {"to": "2965", "prefix": "udies, somnolence resulted in discontinuation for 10.4% of ", "from": "2959", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": "-treated patients, compared to 2.2% for placebo. It is uncle"}, {"to": "3097", "prefix": "ther or not tolerance develops to the somnolent effects of ", "from": "3091", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ". Because of the potentially significant effects of REMERON "}, {"to": "3156", "prefix": "REMERON. Because of the potentially significant effects of ", "from": "3150", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " on impairment of performance, patients should be cautioned "}, {"to": "3789", "prefix": "ies, dizziness was reported in 7% of patients treated with ", "from": "3783", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ", compared to 3% for placebo and 14% for amitriptyline. It i"}, {"to": "3957", "prefix": "s to the dizziness observed in association with the use of ", "from": "3951", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ".\n                           \n                           \n  "}, {"to": "4377", "prefix": "tite increase was reported in 17% of patients treated with ", "from": "4371", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ", compared to 2% for placebo and 6% for amitriptyline. In th"}, {"to": "4545", "prefix": " body weight was reported in 7.5% of patients treated with ", "from": "4535", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ", compared to 0% for placebo and 5.9% for amitriptyline. In "}, {"to": "4733", "prefix": " long-term, open-label treatment, 8% of patients receiving ", "from": "4727", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " discontinued for weight gain. In an 8-week-long pediatric c"}, {"to": "4855", "prefix": "ic clinical trial of doses between 15 to 45 mg/day, 49% of ", "from": "4849", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": "-treated patients had a weight gain of at least 7%, compared"}, {"to": "5456", "prefix": "ts of normal were observed in 15% of patients treated with ", "from": "5450", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ", compared to 7% for placebo and 8% for amitriptyline. In th"}, {"to": "5638", "prefix": "to \u2265500 mg/dL were observed in 6% of patients treated with ", "from": "5628", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ", compared to 3% for placebo and 3% for amitriptyline.\n     "}, {"to": "6160", "prefix": "ange) were observed in 2.0% (8/424) of patients exposed to ", "from": "6154", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " in a pool of short-term US controlled trials, compared to 0"}, {"to": "6555", "prefix": "es, the enzyme levels returned to normal despite continued ", "from": "6549", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " treatment. REMERON should be used with caution in patients "}, {"to": "6574", "prefix": "ls returned to normal despite continued REMERON treatment. ", "from": "6568", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " should be used with caution in patients with impaired hepat"}, {"to": "7101", "prefix": "omania occurred in approximately 0.2% (3/1299 patients) of ", "from": "7095", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": "-treated patients in US studies. Although the incidence of m"}, {"to": "7222", "prefix": "ence of mania/hypomania was very low during treatment with ", "from": "7212", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ", it should be used carefully in patients with a history of "}, {"to": "7717", "prefix": "eported among the 2796 US and non-US patients treated with ", "from": "7711", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ". However, no controlled studies have been carried out in pa"}, {"to": "7864", "prefix": "tory of seizures. Therefore, care should be exercised when ", "from": "7854", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " is used in these patients.\n                           \n    "}, {"to": "8256", "prefix": "   \n                              Clinical experience with ", "from": "8250", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " in patients with concomitant systemic illness is limited. A"}, {"to": "8372", "prefix": " is limited. Accordingly, care is advisable in prescribing ", "from": "8362", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " for patients with diseases or conditions that affect metabo"}, {"to": "8500", "prefix": "sm or hemodynamic responses.\n                              ", "from": "8494", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " has not been systematically evaluated or used to any apprec"}, {"to": "8675", "prefix": " myocardial infarction or other significant heart disease. ", "from": "8669", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " was associated with significant orthostatic hypotension in "}, {"to": "8895", "prefix": "ently observed in clinical trials with depressed patients. ", "from": "8889", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " should be used with caution in patients with known cardiova"}, {"to": "9271", "prefix": "ntihypertensive medication).\n                              ", "from": "9261", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " clearance is decreased in patients with moderate [glomerula"}, {"to": "323", "prefix": "n reports of adverse reactions upon the discontinuation of ", "from": "317", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " (mirtazapine) Tablets (particularly when abrupt), including"}, {"to": "934", "prefix": "e.\n                              Patients currently taking ", "from": "928", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " should NOT discontinue treatment abruptly, due to risk of d"}, {"to": "1100", "prefix": "t a medical decision is made to discontinue treatment with ", "from": "1094", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ", a gradual reduction in the dose, rather than an abrupt ces"}, {"to": "2809", "prefix": "s, somnolence was reported in 54% of patients treated with ", "from": "2803", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " (mirtazapine) Tablets, compared to 18% for placebo and 60% "}, {"to": "2965", "prefix": "udies, somnolence resulted in discontinuation for 10.4% of ", "from": "2959", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": "-treated patients, compared to 2.2% for placebo. It is uncle"}, {"to": "3097", "prefix": "ther or not tolerance develops to the somnolent effects of ", "from": "3091", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ". Because of the potentially significant effects of REMERON "}, {"to": "3156", "prefix": "REMERON. Because of the potentially significant effects of ", "from": "3150", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " on impairment of performance, patients should be cautioned "}, {"to": "3789", "prefix": "ies, dizziness was reported in 7% of patients treated with ", "from": "3783", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ", compared to 3% for placebo and 14% for amitriptyline. It i"}, {"to": "3957", "prefix": "s to the dizziness observed in association with the use of ", "from": "3951", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ".\n                           \n                           \n  "}, {"to": "4377", "prefix": "tite increase was reported in 17% of patients treated with ", "from": "4371", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ", compared to 2% for placebo and 6% for amitriptyline. In th"}, {"to": "4733", "prefix": " long-term, open-label treatment, 8% of patients receiving ", "from": "4727", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " discontinued for weight gain. In an 8-week-long pediatric c"}, {"to": "4855", "prefix": "ic clinical trial of doses between 15 to 45 mg/day, 49% of ", "from": "4849", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": "-treated patients had a weight gain of at least 7%, compared"}, {"to": "5456", "prefix": "ts of normal were observed in 15% of patients treated with ", "from": "5450", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ", compared to 7% for placebo and 8% for amitriptyline. In th"}, {"to": "6160", "prefix": "ange) were observed in 2.0% (8/424) of patients exposed to ", "from": "6154", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " in a pool of short-term US controlled trials, compared to 0"}, {"to": "6555", "prefix": "es, the enzyme levels returned to normal despite continued ", "from": "6549", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " treatment. REMERON should be used with caution in patients "}, {"to": "6574", "prefix": "ls returned to normal despite continued REMERON treatment. ", "from": "6568", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " should be used with caution in patients with impaired hepat"}, {"to": "7101", "prefix": "omania occurred in approximately 0.2% (3/1299 patients) of ", "from": "7095", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": "-treated patients in US studies. Although the incidence of m"}, {"to": "7717", "prefix": "eported among the 2796 US and non-US patients treated with ", "from": "7711", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ". However, no controlled studies have been carried out in pa"}, {"to": "8256", "prefix": "   \n                              Clinical experience with ", "from": "8250", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " in patients with concomitant systemic illness is limited. A"}, {"to": "8500", "prefix": "sm or hemodynamic responses.\n                              ", "from": "8494", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " has not been systematically evaluated or used to any apprec"}, {"to": "8675", "prefix": " myocardial infarction or other significant heart disease. ", "from": "8669", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " was associated with significant orthostatic hypotension in "}, {"to": "8895", "prefix": "ently observed in clinical trials with depressed patients. ", "from": "8889", "name": "Remeron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/134774", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " should be used with caution in patients with known cardiova"}, {"to": "336", "prefix": " of adverse reactions upon the discontinuation of REMERON (", "from": "326", "name": "Mirtazapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/15996", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ") Tablets (particularly when abrupt), including but not limi"}, {"to": "2262", "prefix": "Hyponatremia has been reported very rarely with the use of ", "from": "2252", "name": "Mirtazapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/15996", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ". Caution should be exercised in patients at risk, such as e"}, {"to": "2822", "prefix": "ence was reported in 54% of patients treated with REMERON (", "from": "2812", "name": "Mirtazapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/15996", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ") Tablets, compared to 18% for placebo and 60% for amitripty"}, {"to": "4545", "prefix": " body weight was reported in 7.5% of patients treated with ", "from": "4535", "name": "Mirtazapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/15996", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ", compared to 0% for placebo and 5.9% for amitriptyline. In "}, {"to": "5638", "prefix": "to \u2265500 mg/dL were observed in 6% of patients treated with ", "from": "5628", "name": "Mirtazapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/15996", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ", compared to 3% for placebo and 3% for amitriptyline.\n     "}, {"to": "7222", "prefix": "ence of mania/hypomania was very low during treatment with ", "from": "7212", "name": "Mirtazapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/15996", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ", it should be used carefully in patients with a history of "}, {"to": "7864", "prefix": "tory of seizures. Therefore, care should be exercised when ", "from": "7854", "name": "Mirtazapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/15996", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " is used in these patients.\n                           \n    "}, {"to": "8372", "prefix": " is limited. Accordingly, care is advisable in prescribing ", "from": "8362", "name": "Mirtazapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/15996", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " for patients with diseases or conditions that affect metabo"}, {"to": "9271", "prefix": "ntihypertensive medication).\n                              ", "from": "9261", "name": "Mirtazapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/15996", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " clearance is decreased in patients with moderate [glomerula"}, {"to": "2886", "prefix": "tazapine) Tablets, compared to 18% for placebo and 60% for ", "from": "2874", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". In these studies, somnolence resulted in discontinuation f"}, {"to": "3843", "prefix": "eated with REMERON, compared to 3% for placebo and 14% for ", "from": "3831", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". It is unclear whether or not tolerance develops to the diz"}, {"to": "4430", "prefix": "reated with REMERON, compared to 2% for placebo and 6% for ", "from": "4418", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". In these same trials, weight gain of \u22657% of body weight wa"}, {"to": "4600", "prefix": " with mirtazapine, compared to 0% for placebo and 5.9% for ", "from": "4588", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". In a pool of premarketing US studies, including many patie"}, {"to": "5509", "prefix": "reated with REMERON, compared to 7% for placebo and 8% for ", "from": "5497", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". In these same studies, nonfasting triglyceride increases t"}, {"to": "5691", "prefix": "ed with mirtazapine, compared to 3% for placebo and 3% for ", "from": "5679", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ".\n                           \n                           \n  "}, {"to": "6285", "prefix": "ed to 0.3% (1/328) of placebo patients and 2.0% (3/181) of ", "from": "6273", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": " patients. Most of these patients with ALT increases did not"}, {"to": "2886", "prefix": "tazapine) Tablets, compared to 18% for placebo and 60% for ", "from": "2874", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". In these studies, somnolence resulted in discontinuation f"}, {"to": "3843", "prefix": "eated with REMERON, compared to 3% for placebo and 14% for ", "from": "3831", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". It is unclear whether or not tolerance develops to the diz"}, {"to": "4430", "prefix": "reated with REMERON, compared to 2% for placebo and 6% for ", "from": "4418", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". In these same trials, weight gain of \u22657% of body weight wa"}, {"to": "4600", "prefix": " with mirtazapine, compared to 0% for placebo and 5.9% for ", "from": "4588", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". In a pool of premarketing US studies, including many patie"}, {"to": "5509", "prefix": "reated with REMERON, compared to 7% for placebo and 8% for ", "from": "5497", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ". In these same studies, nonfasting triglyceride increases t"}, {"to": "5691", "prefix": "ed with mirtazapine, compared to 3% for placebo and 3% for ", "from": "5679", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ".\n                           \n                           \n  "}, {"to": "6285", "prefix": "ed to 0.3% (1/328) of placebo patients and 2.0% (3/181) of ", "from": "6273", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": " patients. Most of these patients with ALT increases did not"}, {"to": "5230", "prefix": "   \n                           \n                           ", "from": "5220", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Cholesterol", "suffix": "/Triglycerides\n                           \n                 "}, {"to": "5351", "prefix": "                      In US controlled studies, nonfasting ", "from": "5341", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "cholesterol", "suffix": " increases to \u226520% above the upper limits of normal were obs"}, {"to": "78", "prefix": "CONTRAINDICATIONS\n               \n                  ", "from": "53", "name": "Clomipramine Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/81984", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "Clomipramine hydrochloride", "suffix": " capsules USP are contraindicated in patients with a history"}, {"to": "78", "prefix": "CONTRAINDICATIONS\n               \n                  ", "from": "53", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "Clomipramine hydrochloride", "suffix": " capsules USP are contraindicated in patients with a history"}, {"to": "174", "prefix": "ndicated in patients with a history of hypersensitivity to ", "from": "163", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " or other tricyclic antidepressants.\n               \n       "}, {"to": "500", "prefix": " use of MAOIs intended to treat psychiatric disorders with ", "from": "489", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " or within 14 days of stopping treatment with clomipramine i"}, {"to": "558", "prefix": " clomipramine or within 14 days of stopping treatment with ", "from": "547", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " is contraindicated because of an increased risk of serotoni"}, {"to": "653", "prefix": "use of an increased risk of serotonin syndrome. The use of ", "from": "642", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " within 14 days of stopping an MAOI intended to treat psychi"}, {"to": "1046", "prefix": "                       ).\n                        Starting ", "from": "1035", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " in a patient who is being treated with linezolid or intrave"}, {"to": "1708", "prefix": "l Infarction\n                     \n                        ", "from": "1697", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "Clomipramine", "suffix": " is contraindicated during the acute recovery period after a"}, {"to": "174", "prefix": "ndicated in patients with a history of hypersensitivity to ", "from": "163", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " or other tricyclic antidepressants.\n               \n       "}, {"to": "500", "prefix": " use of MAOIs intended to treat psychiatric disorders with ", "from": "489", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " or within 14 days of stopping treatment with clomipramine i"}, {"to": "558", "prefix": " clomipramine or within 14 days of stopping treatment with ", "from": "547", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " is contraindicated because of an increased risk of serotoni"}, {"to": "653", "prefix": "use of an increased risk of serotonin syndrome. The use of ", "from": "642", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " within 14 days of stopping an MAOI intended to treat psychi"}, {"to": "1046", "prefix": "                       ).\n                        Starting ", "from": "1035", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " in a patient who is being treated with linezolid or intrave"}, {"to": "1708", "prefix": "l Infarction\n                     \n                        ", "from": "1697", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "Clomipramine", "suffix": " is contraindicated during the acute recovery period after a"}, {"to": "619", "prefix": "pramine is contraindicated because of an increased risk of ", "from": "611", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "serotonin", "suffix": " syndrome. The use of clomipramine within 14 days of stoppin"}, {"to": "1191", "prefix": "ue is also contraindicated because of an increased risk of ", "from": "1183", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "serotonin", "suffix": " syndrome (see \n                           \n                "}, {"to": "619", "prefix": "pramine is contraindicated because of an increased risk of ", "from": "611", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "serotonin", "suffix": " syndrome. The use of clomipramine within 14 days of stoppin"}, {"to": "1191", "prefix": "ue is also contraindicated because of an increased risk of ", "from": "1183", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "serotonin", "suffix": " syndrome (see \n                           \n                "}, {"to": "1095", "prefix": "arting clomipramine in a patient who is being treated with ", "from": "1087", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190376", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "linezolid", "suffix": " or intravenous methylene blue is also contraindicated becau"}, {"to": "1095", "prefix": "arting clomipramine in a patient who is being treated with ", "from": "1087", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/MESH/C098010", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "linezolid", "suffix": " or intravenous methylene blue is also contraindicated becau"}, {"to": "1125", "prefix": "patient who is being treated with linezolid or intravenous ", "from": "1112", "name": "Methylene Blue", "fullId": "http://purl.bioontology.org/ontology/MESH/D008751", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "methylene blue", "suffix": " is also contraindicated because of an increased risk of ser"}, {"to": "1125", "prefix": "patient who is being treated with linezolid or intravenous ", "from": "1112", "name": "Methylene blue", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6878", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "methylene blue", "suffix": " is also contraindicated because of an increased risk of ser"}, {"to": "256", "prefix": "       \n                        The mechanism of action of ", "from": "248", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " is unknown. However, it has been proposed that the therapeu"}, {"to": "341", "prefix": "ver, it has been proposed that the therapeutic efficacy of ", "from": "333", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " in schizophrenia is mediated through antagonism of the dopa"}, {"to": "853", "prefix": "macodynamics\n                     \n                        ", "from": "845", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " demonstrated binding affinity to the following receptors: h"}, {"to": "1356", "prefix": "nM), and dopamine D3 (Ki 555 nM). \n                        ", "from": "1348", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " causes little or no prolactin elevation.\n                  "}, {"to": "1493", "prefix": "nical electroencephalogram (EEG) studies demonstrated that ", "from": "1485", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " increases delta and theta activity and slows dominant alpha"}, {"to": "1743", "prefix": " have reported an intensification of dream activity during ", "from": "1735", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " therapy. REM sleep was found to be increased to 85% of the "}, {"to": "2961", "prefix": "tribution\n                        \n                        ", "from": "2953", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is approximately 97% bound to serum proteins. The interacti"}, {"to": "3041", "prefix": "ately 97% bound to serum proteins. The interaction between ", "from": "3033", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and other highly protein-bound drugs has not been fully eva"}, {"to": "3293", "prefix": "Excretion\n                        \n                        ", "from": "3285", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is almost completely metabolized prior to excretion, and on"}, {"to": "3434", "prefix": "nts of unchanged drug are detected in the urine and feces. ", "from": "3426", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is a substrate for many cytochrome P450 isozymes, in partic"}, {"to": "3923", "prefix": "rivatives were inactive. The mean elimination half-life of ", "from": "3915", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " after a single 75 mg dose was 8 hours (range: 4 to12 hours)"}, {"to": "4220", "prefix": "parison of single-dose and multiple-dose administration of ", "from": "4212", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " demonstrated that the elimination half-life increased signi"}, {"to": "4571", "prefix": "h respect to area under the curve (AUC), peak, and minimum ", "from": "4563", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " plasma concentrations were observed after administration of"}, {"to": "4976", "prefix": "dy was conducted in 16 schizophrenic patients who received ", "from": "4968", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " under steady-state conditions. After coadministration of fl"}, {"to": "5098", "prefix": " of fluvoxamine for 14 days, mean trough concentrations of ", "from": "5090", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and its metabolites, N-desmethylclozapine and clozapine N-o"}, {"to": "5447", "prefix": "  In a study of schizophrenic patients (n=14) who received ", "from": "5439", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " under steady-state conditions, coadministration of paroxeti"}, {"to": "5564", "prefix": "of paroxetine produced only minor changes in the levels of ", "from": "5556", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and its metabolites. However, other published reports descr"}, {"to": "5677", "prefix": "d reports describe modest elevations (less than 2-fold) of ", "from": "5669", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and metabolite concentrations when clozapine was taken with"}, {"to": "5722", "prefix": "an 2-fold) of clozapine and metabolite concentrations when ", "from": "5714", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " was taken with paroxetine, fluoxetine, and sertraline.\n    "}, {"to": "6157", "prefix": " of renal or hepatic impairment on the pharmacokinetics of ", "from": "6149", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": ". Higher clozapine plasma concentrations are likely in patie"}, {"to": "6175", "prefix": "ic impairment on the pharmacokinetics of clozapine. Higher ", "from": "6167", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " plasma concentrations are likely in patients with significa"}, {"to": "6596", "prefix": " may develop higher than expected plasma concentrations of ", "from": "6588", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " when given usual doses.\n                     \n             "}, {"to": "256", "prefix": "       \n                        The mechanism of action of ", "from": "248", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " is unknown. However, it has been proposed that the therapeu"}, {"to": "341", "prefix": "ver, it has been proposed that the therapeutic efficacy of ", "from": "333", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " in schizophrenia is mediated through antagonism of the dopa"}, {"to": "472", "prefix": " type 2 (D2) and the serotonin type 2A (5-HT2A) receptors. ", "from": "465", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " also acts as an antagonist at adrenergic, cholinergic, hist"}, {"to": "853", "prefix": "macodynamics\n                     \n                        ", "from": "845", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " demonstrated binding affinity to the following receptors: h"}, {"to": "1356", "prefix": "nM), and dopamine D3 (Ki 555 nM). \n                        ", "from": "1348", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " causes little or no prolactin elevation.\n                  "}, {"to": "1493", "prefix": "nical electroencephalogram (EEG) studies demonstrated that ", "from": "1485", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " increases delta and theta activity and slows dominant alpha"}, {"to": "1743", "prefix": " have reported an intensification of dream activity during ", "from": "1735", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " therapy. REM sleep was found to be increased to 85% of the "}, {"to": "2271", "prefix": "                       \n                        In humans, ", "from": "2264", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " tablets (25 mg and 100 mg) are equally bioavailable relativ"}, {"to": "2346", "prefix": " (25 mg and 100 mg) are equally bioavailable relative to a ", "from": "2339", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " solution. Following oral administration of CLOZARIL 100 mg "}, {"to": "2398", "prefix": "e to a CLOZARIL solution. Following oral administration of ", "from": "2391", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " 100 mg twice daily, the average steady-state peak plasma co"}, {"to": "2779", "prefix": " does not appear to affect the systemic bioavailability of ", "from": "2772", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": ". Thus, CLOZARIL may be administered with or without food.\n "}, {"to": "2795", "prefix": " to affect the systemic bioavailability of CLOZARIL. Thus, ", "from": "2788", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " may be administered with or without food.\n                 "}, {"to": "2961", "prefix": "tribution\n                        \n                        ", "from": "2953", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is approximately 97% bound to serum proteins. The interacti"}, {"to": "3041", "prefix": "ately 97% bound to serum proteins. The interaction between ", "from": "3033", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and other highly protein-bound drugs has not been fully eva"}, {"to": "3293", "prefix": "Excretion\n                        \n                        ", "from": "3285", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is almost completely metabolized prior to excretion, and on"}, {"to": "3434", "prefix": "nts of unchanged drug are detected in the urine and feces. ", "from": "3426", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is a substrate for many cytochrome P450 isozymes, in partic"}, {"to": "3923", "prefix": "rivatives were inactive. The mean elimination half-life of ", "from": "3915", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " after a single 75 mg dose was 8 hours (range: 4 to12 hours)"}, {"to": "4220", "prefix": "parison of single-dose and multiple-dose administration of ", "from": "4212", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " demonstrated that the elimination half-life increased signi"}, {"to": "4571", "prefix": "h respect to area under the curve (AUC), peak, and minimum ", "from": "4563", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " plasma concentrations were observed after administration of"}, {"to": "4976", "prefix": "dy was conducted in 16 schizophrenic patients who received ", "from": "4968", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " under steady-state conditions. After coadministration of fl"}, {"to": "5098", "prefix": " of fluvoxamine for 14 days, mean trough concentrations of ", "from": "5090", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and its metabolites, N-desmethylclozapine and clozapine N-o"}, {"to": "5447", "prefix": "  In a study of schizophrenic patients (n=14) who received ", "from": "5439", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " under steady-state conditions, coadministration of paroxeti"}, {"to": "5564", "prefix": "of paroxetine produced only minor changes in the levels of ", "from": "5556", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and its metabolites. However, other published reports descr"}, {"to": "5677", "prefix": "d reports describe modest elevations (less than 2-fold) of ", "from": "5669", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and metabolite concentrations when clozapine was taken with"}, {"to": "5722", "prefix": "an 2-fold) of clozapine and metabolite concentrations when ", "from": "5714", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " was taken with paroxetine, fluoxetine, and sertraline.\n    "}, {"to": "6157", "prefix": " of renal or hepatic impairment on the pharmacokinetics of ", "from": "6149", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": ". Higher clozapine plasma concentrations are likely in patie"}, {"to": "6175", "prefix": "ic impairment on the pharmacokinetics of clozapine. Higher ", "from": "6167", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " plasma concentrations are likely in patients with significa"}, {"to": "6596", "prefix": " may develop higher than expected plasma concentrations of ", "from": "6588", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " when given usual doses.\n                     \n             "}, {"to": "405", "prefix": "ine in schizophrenia is mediated through antagonism of the ", "from": "398", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " type 2 (D2) and the serotonin type 2A (5-HT2A) receptors. C"}, {"to": "1117", "prefix": "serotonin 5-HT7 (Ki 6.3 nM), serotonin 5-HT2C (Ki 9.4 nM), ", "from": "1110", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D4 (Ki 24 nM), adrenergic \u03b12A (Ki 90 nM), serotonin 5-HT3 ("}, {"to": "1226", "prefix": " serotonin 5-HT3 (Ki 95 nM), serotonin 5-HT1A (Ki 120 nM), ", "from": "1219", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D2 (Ki 160 nM), dopamine D1 (Ki 270 nM), dopamine D5 (Ki 45"}, {"to": "1251", "prefix": "M), serotonin 5-HT1A (Ki 120 nM), dopamine D2 (Ki 160 nM), ", "from": "1244", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D1 (Ki 270 nM), dopamine D5 (Ki 454 nM), and dopamine D3 (K"}, {"to": "1276", "prefix": "120 nM), dopamine D2 (Ki 160 nM), dopamine D1 (Ki 270 nM), ", "from": "1269", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D5 (Ki 454 nM), and dopamine D3 (Ki 555 nM). \n             "}, {"to": "1305", "prefix": "nM), dopamine D1 (Ki 270 nM), dopamine D5 (Ki 454 nM), and ", "from": "1298", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D3 (Ki 555 nM). \n                        Clozapine causes l"}, {"to": "405", "prefix": "ine in schizophrenia is mediated through antagonism of the ", "from": "398", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " type 2 (D2) and the serotonin type 2A (5-HT2A) receptors. C"}, {"to": "1117", "prefix": "serotonin 5-HT7 (Ki 6.3 nM), serotonin 5-HT2C (Ki 9.4 nM), ", "from": "1110", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D4 (Ki 24 nM), adrenergic \u03b12A (Ki 90 nM), serotonin 5-HT3 ("}, {"to": "1226", "prefix": " serotonin 5-HT3 (Ki 95 nM), serotonin 5-HT1A (Ki 120 nM), ", "from": "1219", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D2 (Ki 160 nM), dopamine D1 (Ki 270 nM), dopamine D5 (Ki 45"}, {"to": "1251", "prefix": "M), serotonin 5-HT1A (Ki 120 nM), dopamine D2 (Ki 160 nM), ", "from": "1244", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D1 (Ki 270 nM), dopamine D5 (Ki 454 nM), and dopamine D3 (K"}, {"to": "1276", "prefix": "120 nM), dopamine D2 (Ki 160 nM), dopamine D1 (Ki 270 nM), ", "from": "1269", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D5 (Ki 454 nM), and dopamine D3 (Ki 555 nM). \n             "}, {"to": "1305", "prefix": "nM), dopamine D1 (Ki 270 nM), dopamine D5 (Ki 454 nM), and ", "from": "1298", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D3 (Ki 555 nM). \n                        Clozapine causes l"}, {"to": "435", "prefix": "ted through antagonism of the dopamine type 2 (D2) and the ", "from": "427", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " type 2A (5-HT2A) receptors. CLOZARIL also acts as an antago"}, {"to": "975", "prefix": "ors: histamine H1 (Ki 1.1 nM), adrenergic \u03b11A (Ki 1.6 nM), ", "from": "967", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT6 (Ki 4 nM), serotonin 5-HT2A (Ki 5.4 nM), muscarinic M"}, {"to": "1002", "prefix": "M), adrenergic \u03b11A (Ki 1.6 nM), serotonin 5-HT6 (Ki 4 nM), ", "from": "994", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT2A (Ki 5.4 nM), muscarinic M1 (Ki 6.2 nM), serotonin 5-"}, {"to": "1059", "prefix": ", serotonin 5-HT2A (Ki 5.4 nM), muscarinic M1 (Ki 6.2 nM), ", "from": "1051", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT7 (Ki 6.3 nM), serotonin 5-HT2C (Ki 9.4 nM), dopamine D"}, {"to": "1088", "prefix": "), muscarinic M1 (Ki 6.2 nM), serotonin 5-HT7 (Ki 6.3 nM), ", "from": "1080", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT2C (Ki 9.4 nM), dopamine D4 (Ki 24 nM), adrenergic \u03b12A "}, {"to": "1169", "prefix": ".4 nM), dopamine D4 (Ki 24 nM), adrenergic \u03b12A (Ki 90 nM), ", "from": "1161", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT3 (Ki 95 nM), serotonin 5-HT1A (Ki 120 nM), dopamine D2"}, {"to": "1197", "prefix": "M), adrenergic \u03b12A (Ki 90 nM), serotonin 5-HT3 (Ki 95 nM), ", "from": "1189", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT1A (Ki 120 nM), dopamine D2 (Ki 160 nM), dopamine D1 (K"}, {"to": "435", "prefix": "ted through antagonism of the dopamine type 2 (D2) and the ", "from": "427", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " type 2A (5-HT2A) receptors. CLOZARIL also acts as an antago"}, {"to": "975", "prefix": "ors: histamine H1 (Ki 1.1 nM), adrenergic \u03b11A (Ki 1.6 nM), ", "from": "967", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT6 (Ki 4 nM), serotonin 5-HT2A (Ki 5.4 nM), muscarinic M"}, {"to": "1002", "prefix": "M), adrenergic \u03b11A (Ki 1.6 nM), serotonin 5-HT6 (Ki 4 nM), ", "from": "994", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT2A (Ki 5.4 nM), muscarinic M1 (Ki 6.2 nM), serotonin 5-"}, {"to": "1059", "prefix": ", serotonin 5-HT2A (Ki 5.4 nM), muscarinic M1 (Ki 6.2 nM), ", "from": "1051", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT7 (Ki 6.3 nM), serotonin 5-HT2C (Ki 9.4 nM), dopamine D"}, {"to": "1088", "prefix": "), muscarinic M1 (Ki 6.2 nM), serotonin 5-HT7 (Ki 6.3 nM), ", "from": "1080", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT2C (Ki 9.4 nM), dopamine D4 (Ki 24 nM), adrenergic \u03b12A "}, {"to": "1169", "prefix": ".4 nM), dopamine D4 (Ki 24 nM), adrenergic \u03b12A (Ki 90 nM), ", "from": "1161", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT3 (Ki 95 nM), serotonin 5-HT1A (Ki 120 nM), dopamine D2"}, {"to": "1197", "prefix": "M), adrenergic \u03b12A (Ki 90 nM), serotonin 5-HT3 (Ki 95 nM), ", "from": "1189", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT1A (Ki 120 nM), dopamine D2 (Ki 160 nM), dopamine D1 (K"}, {"to": "472", "prefix": " type 2 (D2) and the serotonin type 2A (5-HT2A) receptors. ", "from": "465", "name": "Clozaril", "fullId": "http://purl.bioontology.org/ontology/RXNORM/216102", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " also acts as an antagonist at adrenergic, cholinergic, hist"}, {"to": "2271", "prefix": "                       \n                        In humans, ", "from": "2264", "name": "Clozaril", "fullId": "http://purl.bioontology.org/ontology/RXNORM/216102", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " tablets (25 mg and 100 mg) are equally bioavailable relativ"}, {"to": "2346", "prefix": " (25 mg and 100 mg) are equally bioavailable relative to a ", "from": "2339", "name": "Clozaril", "fullId": "http://purl.bioontology.org/ontology/RXNORM/216102", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " solution. Following oral administration of CLOZARIL 100 mg "}, {"to": "2398", "prefix": "e to a CLOZARIL solution. Following oral administration of ", "from": "2391", "name": "Clozaril", "fullId": "http://purl.bioontology.org/ontology/RXNORM/216102", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " 100 mg twice daily, the average steady-state peak plasma co"}, {"to": "2779", "prefix": " does not appear to affect the systemic bioavailability of ", "from": "2772", "name": "Clozaril", "fullId": "http://purl.bioontology.org/ontology/RXNORM/216102", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": ". Thus, CLOZARIL may be administered with or without food.\n "}, {"to": "2795", "prefix": " to affect the systemic bioavailability of CLOZARIL. Thus, ", "from": "2788", "name": "Clozaril", "fullId": "http://purl.bioontology.org/ontology/RXNORM/216102", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " may be administered with or without food.\n                 "}, {"to": "921", "prefix": " demonstrated binding affinity to the following receptors: ", "from": "913", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "histamine", "suffix": " H1 (Ki 1.1 nM), adrenergic \u03b11A (Ki 1.6 nM), serotonin 5-HT6"}, {"to": "921", "prefix": " demonstrated binding affinity to the following receptors: ", "from": "913", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "histamine", "suffix": " H1 (Ki 1.1 nM), adrenergic \u03b11A (Ki 1.6 nM), serotonin 5-HT6"}, {"to": "1386", "prefix": "M). \n                        Clozapine causes little or no ", "from": "1378", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "prolactin", "suffix": " elevation.\n                        Clinical electroencephal"}, {"to": "1386", "prefix": "M). \n                        Clozapine causes little or no ", "from": "1378", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1426890", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "prolactin", "suffix": " elevation.\n                        Clinical electroencephal"}, {"to": "3785", "prefix": "harmacological testing has shown the desmethyl metabolite (", "from": "3774", "name": "norclozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058272", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "norclozapine", "suffix": ") to have only limited activity, while the hydroxylated and "}, {"to": "5140", "prefix": "an trough concentrations of clozapine and its metabolites, ", "from": "5121", "name": "norclozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058272", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "N-desmethylclozapine", "suffix": " and clozapine N-oxide, were elevated about 3-fold compared "}, {"to": "4836", "prefix": "      \n                        \n                           ", "from": "4826", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42355", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Fluvoxamine", "suffix": " \n                        \n                        A pharmac"}, {"to": "5045", "prefix": "e under steady-state conditions. After coadministration of ", "from": "5035", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42355", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "fluvoxamine", "suffix": " for 14 days, mean trough concentrations of clozapine and it"}, {"to": "4836", "prefix": "      \n                        \n                           ", "from": "4826", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Fluvoxamine", "suffix": " \n                        \n                        A pharmac"}, {"to": "5045", "prefix": "e under steady-state conditions. After coadministration of ", "from": "5035", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "fluvoxamine", "suffix": " for 14 days, mean trough concentrations of clozapine and it"}, {"to": "5303", "prefix": "tions.\n                        \n                           ", "from": "5294", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Paroxetine", "suffix": ", Fluoxetine, and Sertraline\n                        \n      "}, {"to": "5509", "prefix": "ozapine under steady-state conditions, coadministration of ", "from": "5500", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "paroxetine", "suffix": " produced only minor changes in the levels of clozapine and "}, {"to": "5748", "prefix": "nd metabolite concentrations when clozapine was taken with ", "from": "5739", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "paroxetine", "suffix": ", fluoxetine, and sertraline.\n                        \n     "}, {"to": "5303", "prefix": "tions.\n                        \n                           ", "from": "5294", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Paroxetine", "suffix": ", Fluoxetine, and Sertraline\n                        \n      "}, {"to": "5509", "prefix": "ozapine under steady-state conditions, coadministration of ", "from": "5500", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "paroxetine", "suffix": " produced only minor changes in the levels of clozapine and "}, {"to": "5748", "prefix": "nd metabolite concentrations when clozapine was taken with ", "from": "5739", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "paroxetine", "suffix": ", fluoxetine, and sertraline.\n                        \n     "}, {"to": "5315", "prefix": "                   \n                           Paroxetine, ", "from": "5306", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Fluoxetine", "suffix": ", and Sertraline\n                        \n                  "}, {"to": "5760", "prefix": "e concentrations when clozapine was taken with paroxetine, ", "from": "5751", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "fluoxetine", "suffix": ", and sertraline.\n                        \n                 "}, {"to": "5315", "prefix": "                   \n                           Paroxetine, ", "from": "5306", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Fluoxetine", "suffix": ", and Sertraline\n                        \n                  "}, {"to": "5760", "prefix": "e concentrations when clozapine was taken with paroxetine, ", "from": "5751", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "fluoxetine", "suffix": ", and sertraline.\n                        \n                 "}, {"to": "5331", "prefix": "   \n                           Paroxetine, Fluoxetine, and ", "from": "5322", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Sertraline", "suffix": "\n                        \n                        In a study"}, {"to": "5776", "prefix": " when clozapine was taken with paroxetine, fluoxetine, and ", "from": "5767", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "sertraline", "suffix": ".\n                        \n                           Specif"}, {"to": "5331", "prefix": "   \n                           Paroxetine, Fluoxetine, and ", "from": "5322", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Sertraline", "suffix": "\n                        \n                        In a study"}, {"to": "5776", "prefix": " when clozapine was taken with paroxetine, fluoxetine, and ", "from": "5767", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "sertraline", "suffix": ".\n                        \n                           Specif"}, {"to": "189", "prefix": "istration of Drugs Highly Bound to Plasma Proteins\u2013Because ", "from": "180", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is tightly bound to plasma protein, the administration of s"}, {"to": "272", "prefix": " is tightly bound to plasma protein, the administration of ", "from": "249", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " to a patient taking another drug which is tightly bound to "}, {"to": "539", "prefix": "erse effects may result from displacement of protein bound ", "from": "530", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " by other tightly bound drugs.\n                        In a "}, {"to": "751", "prefix": "0.75 mg/kg) before and after 21 days of dosing with either ", "from": "742", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " (50 to 200 mg/day) or placebo, there was a mean increase in"}, {"to": "870", "prefix": "ncrease in prothrombin time of 8% relative to baseline for ", "from": "861", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " compared to a 1% decrease for placebo (p "}, {"to": "189", "prefix": "istration of Drugs Highly Bound to Plasma Proteins\u2013Because ", "from": "180", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is tightly bound to plasma protein, the administration of s"}, {"to": "539", "prefix": "erse effects may result from displacement of protein bound ", "from": "530", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " by other tightly bound drugs.\n                        In a "}, {"to": "751", "prefix": "0.75 mg/kg) before and after 21 days of dosing with either ", "from": "742", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " (50 to 200 mg/day) or placebo, there was a mean increase in"}, {"to": "870", "prefix": "ncrease in prothrombin time of 8% relative to baseline for ", "from": "861", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " compared to a 1% decrease for placebo (p "}, {"to": "272", "prefix": " is tightly bound to plasma protein, the administration of ", "from": "249", "name": "Sertraline Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/155137", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " to a patient taking another drug which is tightly bound to "}, {"to": "355", "prefix": "king another drug which is tightly bound to protein (e.g., ", "from": "348", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "warfarin", "suffix": ", digitoxin) may cause a shift in plasma concentrations pote"}, {"to": "680", "prefix": "g prothrombin time AUC (0 to 120 hr) following dosing with ", "from": "673", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "warfarin", "suffix": " (0.75 mg/kg) before and after 21 days of dosing with either"}, {"to": "355", "prefix": "king another drug which is tightly bound to protein (e.g., ", "from": "348", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "warfarin", "suffix": ", digitoxin) may cause a shift in plasma concentrations pote"}, {"to": "680", "prefix": "g prothrombin time AUC (0 to 120 hr) following dosing with ", "from": "673", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "warfarin", "suffix": " (0.75 mg/kg) before and after 21 days of dosing with either"}, {"to": "366", "prefix": "er drug which is tightly bound to protein (e.g., warfarin, ", "from": "358", "name": "Digitoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3403", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "digitoxin", "suffix": ") may cause a shift in plasma concentrations potentially res"}, {"to": "366", "prefix": "er drug which is tightly bound to protein (e.g., warfarin, ", "from": "358", "name": "Digitoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004074", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "digitoxin", "suffix": ") may cause a shift in plasma concentrations potentially res"}, {"to": "626", "prefix": " bound drugs.\n                        In a study comparing ", "from": "616", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "prothrombin", "suffix": " time AUC (0 to 120 hr) following dosing with warfarin (0.75"}, {"to": "823", "prefix": "50 to 200 mg/day) or placebo, there was a mean increase in ", "from": "813", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "prothrombin", "suffix": " time of 8% relative to baseline for sertraline compared to "}, {"to": "626", "prefix": " bound drugs.\n                        In a study comparing ", "from": "616", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1441688", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "prothrombin", "suffix": " time AUC (0 to 120 hr) following dosing with warfarin (0.75"}, {"to": "823", "prefix": "50 to 200 mg/day) or placebo, there was a mean increase in ", "from": "813", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1441688", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "prothrombin", "suffix": " time of 8% relative to baseline for sertraline compared to "}, {"to": "384", "prefix": "ith antipsychotic drugs are at an increased risk of death. ", "from": "361", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine maleate", "suffix": " is not approved for the treatment of patients with dementia"}, {"to": "609", "prefix": "  The extrapyramidal symptoms which can occur secondary to ", "from": "594", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " may be confused with the central nervous system signs of an"}, {"to": "802", "prefix": " e.g., Reye\u2019s syndrome or other encephalopathy. The use of ", "from": "787", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " and other potential hepatotoxins should be avoided in child"}, {"to": "6602", "prefix": "nothiazine should not receive any phenothiazine, including ", "from": "6587", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": ", unless in the judgment of the physician the potential bene"}, {"to": "6751", "prefix": "ent outweigh the possible hazards.\n                        ", "from": "6736", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine", "suffix": " may impair mental and/or physical abilities, especially dur"}, {"to": "7379", "prefix": "            \n                        Safety for the use of ", "from": "7364", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " during pregnancy has not been established. Therefore, proch"}, {"to": "7450", "prefix": "zine during pregnancy has not been established. Therefore, ", "from": "7435", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " is not recommended for use in pregnant patients except in c"}, {"to": "8699", "prefix": "d prolonged hospitalization.\n                              ", "from": "8676", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine Maleate", "suffix": " should be used during pregnancy only if the potential benef"}, {"to": "9244", "prefix": " milk of nursing mothers. Caution should be exercised when ", "from": "9229", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " is administered to a nursing woman.\n                     \n "}, {"to": "384", "prefix": "ith antipsychotic drugs are at an increased risk of death. ", "from": "361", "name": "Prochlorperazine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8706", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine maleate", "suffix": " is not approved for the treatment of patients with dementia"}, {"to": "8699", "prefix": "d prolonged hospitalization.\n                              ", "from": "8676", "name": "Prochlorperazine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8706", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine Maleate", "suffix": " should be used during pregnancy only if the potential benef"}, {"to": "609", "prefix": "  The extrapyramidal symptoms which can occur secondary to ", "from": "594", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8704", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " may be confused with the central nervous system signs of an"}, {"to": "802", "prefix": " e.g., Reye\u2019s syndrome or other encephalopathy. The use of ", "from": "787", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8704", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " and other potential hepatotoxins should be avoided in child"}, {"to": "6602", "prefix": "nothiazine should not receive any phenothiazine, including ", "from": "6587", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8704", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": ", unless in the judgment of the physician the potential bene"}, {"to": "6751", "prefix": "ent outweigh the possible hazards.\n                        ", "from": "6736", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8704", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine", "suffix": " may impair mental and/or physical abilities, especially dur"}, {"to": "7379", "prefix": "            \n                        Safety for the use of ", "from": "7364", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8704", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " during pregnancy has not been established. Therefore, proch"}, {"to": "7450", "prefix": "zine during pregnancy has not been established. Therefore, ", "from": "7435", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8704", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " is not recommended for use in pregnant patients except in c"}, {"to": "9244", "prefix": " milk of nursing mothers. Caution should be exercised when ", "from": "9229", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8704", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " is administered to a nursing woman.\n                     \n "}, {"to": "6537", "prefix": "itivity reaction (e.g., blood dyscrasias, jaundice) with a ", "from": "6525", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "phenothiazine", "suffix": " should not receive any phenothiazine, including prochlorper"}, {"to": "6574", "prefix": "ias, jaundice) with a phenothiazine should not receive any ", "from": "6562", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "phenothiazine", "suffix": ", including prochlorperazine, unless in the judgment of the "}, {"to": "134", "prefix": "             \n                        \u2022Hypersensitivity to ", "from": "123", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " or any components of the formulation. Angioedema has been r"}, {"to": "1236", "prefix": "       \n                              \u2022Hypersensitivity to ", "from": "1225", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " or any components of the BRINTELLIX formulation (4).\n      "}, {"to": "134", "prefix": "             \n                        \u2022Hypersensitivity to ", "from": "123", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " or any components of the formulation. Angioedema has been r"}, {"to": "1236", "prefix": "       \n                              \u2022Hypersensitivity to ", "from": "1225", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " or any components of the BRINTELLIX formulation (4).\n      "}, {"to": "237", "prefix": "ion. Angioedema has been reported in patients treated with ", "from": "228", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": ".\n                     \n                        \u2022The use of "}, {"to": "358", "prefix": " use of MAOIs intended to treat psychiatric disorders with ", "from": "349", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " or within 21 days of stopping treatment with BRINTELLIX is "}, {"to": "414", "prefix": "th BRINTELLIX or within 21 days of stopping treatment with ", "from": "405", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " is contraindicated because of an increased risk of serotoni"}, {"to": "507", "prefix": "use of an increased risk of serotonin syndrome. The use of ", "from": "498", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " within 14 days of stopping an MAOI intended to treat psychi"}, {"to": "769", "prefix": "  \n                     \n                        \u00a0Starting ", "from": "760", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " in a patient who is being treated with MAOIs such as linezo"}, {"to": "1272", "prefix": "\u2022Hypersensitivity to vortioxetine or any components of the ", "from": "1263", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " formulation (4).\n                           \n              "}, {"to": "1459", "prefix": "not use MAOIs intended to treat psychiatric disorders with ", "from": "1450", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " or within 21 days of stopping treatment with BRINTELLIX. Do"}, {"to": "1515", "prefix": "th BRINTELLIX or within 21 days of stopping treatment with ", "from": "1506", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": ". Do not use BRINTELLIX within 14 days of stopping an MAOI i"}, {"to": "1538", "prefix": " 21 days of stopping treatment with BRINTELLIX. Do not use ", "from": "1529", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " within 14 days of stopping an MAOI intended to treat psychi"}, {"to": "1651", "prefix": " to treat psychiatric disorders. In addition, do not start ", "from": "1642", "name": "Brintellix", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1439824", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " in a patient who is being treated with linezolid or intrave"}, {"to": "475", "prefix": "NTELLIX is contraindicated because of an increased risk of ", "from": "467", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " syndrome. The use of BRINTELLIX within 14 days of stopping "}, {"to": "928", "prefix": "ue is also contraindicated because of an increased risk of ", "from": "920", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " syndrome [see Dosage and Administration (2.5) and Warnings "}, {"to": "475", "prefix": "NTELLIX is contraindicated because of an increased risk of ", "from": "467", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " syndrome. The use of BRINTELLIX within 14 days of stopping "}, {"to": "928", "prefix": "ue is also contraindicated because of an increased risk of ", "from": "920", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " syndrome [see Dosage and Administration (2.5) and Warnings "}, {"to": "832", "prefix": "ELLIX in a patient who is being treated with MAOIs such as ", "from": "824", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190376", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "linezolid", "suffix": " or intravenous methylene blue is also contraindicated becau"}, {"to": "1700", "prefix": "ot start BRINTELLIX in a patient who is being treated with ", "from": "1692", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190376", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "linezolid", "suffix": " or intravenous methylene blue (4).\n                        "}, {"to": "832", "prefix": "ELLIX in a patient who is being treated with MAOIs such as ", "from": "824", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/MESH/C098010", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "linezolid", "suffix": " or intravenous methylene blue is also contraindicated becau"}, {"to": "1700", "prefix": "ot start BRINTELLIX in a patient who is being treated with ", "from": "1692", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/MESH/C098010", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "linezolid", "suffix": " or intravenous methylene blue (4).\n                        "}, {"to": "862", "prefix": " being treated with MAOIs such as linezolid or intravenous ", "from": "849", "name": "Methylene Blue", "fullId": "http://purl.bioontology.org/ontology/MESH/D008751", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "methylene blue", "suffix": " is also contraindicated because of an increased risk of ser"}, {"to": "1730", "prefix": "patient who is being treated with linezolid or intravenous ", "from": "1717", "name": "Methylene Blue", "fullId": "http://purl.bioontology.org/ontology/MESH/D008751", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "methylene blue", "suffix": " (4).\n                        \n                     \n       "}, {"to": "862", "prefix": " being treated with MAOIs such as linezolid or intravenous ", "from": "849", "name": "Methylene blue", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6878", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "methylene blue", "suffix": " is also contraindicated because of an increased risk of ser"}, {"to": "1730", "prefix": "patient who is being treated with linezolid or intravenous ", "from": "1717", "name": "Methylene blue", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6878", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "methylene blue", "suffix": " (4).\n                        \n                     \n       "}, {"to": "67", "prefix": "CONTRAINDICATIONS\n               \n                  ", "from": "53", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "Benzodiazepines", "suffix": " may cause fetal damage when administered during pregnancy. "}, {"to": "471", "prefix": "henomena following the ingestion of therapeutic doses of a ", "from": "458", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzodiazepine", "suffix": " hypnotic during the last weeks of pregnancy.\n              "}, {"to": "208", "prefix": "isk of congenital malformations associated with the use of ", "from": "201", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "diazepam", "suffix": " and chlordiazepoxide during the first trimester of pregnanc"}, {"to": "208", "prefix": "isk of congenital malformations associated with the use of ", "from": "201", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D003975", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "diazepam", "suffix": " and chlordiazepoxide during the first trimester of pregnanc"}, {"to": "229", "prefix": "ital malformations associated with the use of diazepam and ", "from": "214", "name": "Chlordiazepoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/D002707", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "chlordiazepoxide", "suffix": " during the first trimester of pregnancy has been suggested "}, {"to": "229", "prefix": "ital malformations associated with the use of diazepam and ", "from": "214", "name": "Chlordiazepoxide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2356", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "chlordiazepoxide", "suffix": " during the first trimester of pregnancy has been suggested "}, {"to": "544", "prefix": "otic during the last weeks of pregnancy.\n                  ", "from": "536", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "Estazolam", "suffix": " is contraindicated in pregnant women. If there is a likelih"}, {"to": "666", "prefix": "ikelihood of the patient becoming pregnant while receiving ", "from": "658", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " she should be warned of the potential risk to the fetus and"}, {"to": "944", "prefix": "itution of therapy should be considered.\n                  ", "from": "936", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "Estazolam", "suffix": " is contraindicated with ketoconazole and itraconazole, sinc"}, {"to": "544", "prefix": "otic during the last weeks of pregnancy.\n                  ", "from": "536", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D004949", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "Estazolam", "suffix": " is contraindicated in pregnant women. If there is a likelih"}, {"to": "666", "prefix": "ikelihood of the patient becoming pregnant while receiving ", "from": "658", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D004949", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " she should be warned of the potential risk to the fetus and"}, {"to": "944", "prefix": "itution of therapy should be considered.\n                  ", "from": "936", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D004949", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "Estazolam", "suffix": " is contraindicated with ketoconazole and itraconazole, sinc"}, {"to": "981", "prefix": "dered.\n                  Estazolam is contraindicated with ", "from": "970", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "ketoconazole", "suffix": " and itraconazole, since these medications significantly imp"}, {"to": "981", "prefix": "dered.\n                  Estazolam is contraindicated with ", "from": "970", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "ketoconazole", "suffix": " and itraconazole, since these medications significantly imp"}, {"to": "998", "prefix": "        Estazolam is contraindicated with ketoconazole and ", "from": "987", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "itraconazole", "suffix": ", since these medications significantly impair oxidative met"}, {"to": "998", "prefix": "        Estazolam is contraindicated with ketoconazole and ", "from": "987", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D017964", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "itraconazole", "suffix": ", since these medications significantly impair oxidative met"}]